ClinicalTrials.gg

Lymphoma, Mantle-Cell clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,221 studies for Lymphoma, Mantle-Cell across more than 10 countries. 154 are recruiting or about to start. 342 of them are mainly about Lymphoma, Mantle-Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 1,256 studies for Lymphoma, Mantle-Cell. How that becomes 1,221 here

This page counts the studies the registry files under Lymphoma, Mantle-Cell, and those it files under no condition that list Lymphoma, Mantle-Cellthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count

  1. 1,256Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −9List Lymphoma, Mantle-Cell as a condition, but the registry did not file them under itMost often written as “Mantle Cell Lymphoma Recurrent” (4), “Mantle Cell Lymphoma Refractory” (2), and “B-cell Mantle Cell Lymphoma” (1). The registry filed them under other conditions only, most often Leukemia, Lymphocytic, Chronic, B-Cell (6) and Lymphoma, Large B-Cell, Diffuse (5).
  3. −26Match it another way12 name it in the title, 1 in a keyword, and 13 by a synonym or other text the search reads.
  4. 1,221The count on this page9 of them list Lymphoma, Mantle-Cell in their own words; the registry filed them under no condition.

Status

Completed
683
Terminated
167
Recruiting
124
Active, not recruiting
86
Status unknown
76
Withdrawn
51

Phase

Phase 2
609
Phase 1
521
Phase 3
87
Early Phase 1
15
Phase 4
6

Where

United States
905
China
98
France
82
Italy
81
Germany
74
United Kingdom
63

Who develops what

Add Lymphoma, Mantle-Cell to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 14 programs from 12 companies, 10 with this as their studies’ main aim; 4 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Huadong Medicine, Lupeng Pharmaceutical and Ascentage Pharma Group International here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
RituximabRecent, repeated
Evidence
  • NCT07855016 · TransThera Sciences (Nanjing), Inc. · Phase 2 · live · background · “Rituximab” · registered Sep 2026
  • NCT07029737 · AstraZeneca · Phase 2 · live · background · “Acalabrutinib combination with Rituximab” · registered Jun 2025
  • NCT06564038 · AstraZeneca · Phase 2 · live · background · “Rituximab” · registered Aug 2024
  • NCT06363994 · InnoCare Pharma Limited · Phase 3 · live · background · “Rituximab” · registered Apr 2024
  • NCT05564052 · Johnson & Johnson · Phase 2 · background · “Rituximab” · registered Sep 2022
Hoffmann-La Roche45% of its industry studiesUS: Hoffmann-La Roche (FDA 1997) + 3 othersEU: Hoffmann-La Roche (EMA 1998) + 6 others45 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT07569965 · Miltenyi Biomedicine GmbH · Phase 2 · live · background · “Cyclophosphamide” · registered Apr 2026
  • NCT06564038 · AstraZeneca · Phase 2 · live · background · “Cyclophosphamide” · registered Aug 2024
  • NCT06253663 · Gilead Sciences · Phase 2 · live · background · “Cyclophosphamide” · registered Feb 2024
  • NCT05155215 · Imunopharm Technology Co., Ltd. · Phase 2 · background · “Cyclophosphamide” · registered Nov 2021
  • NCT04880434 · Gilead Sciences · Phase 2 · background · “Cyclophosphamide” · registered Apr 2021
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed44 studies
fludarabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07569965 · Miltenyi Biomedicine GmbH · Phase 2 · live · background · “Fludarabine” · registered Apr 2026
  • NCT06253663 · Gilead Sciences · Phase 2 · live · background · “Fludarabine” · registered Feb 2024
  • NCT05155215 · Imunopharm Technology Co., Ltd. · Phase 2 · background · “Fludarabine” · registered Nov 2021
  • NCT04880434 · Gilead Sciences · Phase 2 · background · “Fludarabine” · registered Apr 2021
  • NCT04792489 · Miltenyi Biomedicine GmbH · Phase 2 · live · background · “Fludarabine” · registered Feb 2021
Beijing Biotech18% of its industry studies33 studies

12 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
acalabrutinibApproved: US 2017 · EU 2020☆ Track1 live phase-3 study: NCT02972840AstraZeneca
sonrotoclaxApproved: US 2026☆ Track1 live phase-3 study: NCT06742996BeOne Medicines
rocbrutinib☆ Track1 live phase-3 study: NCT07377578Lupeng Pharmaceutical Ltd.
mesutoclax☆ Track1 live phase-3 study: NCT07784101InnoCare Pharma Limited

The 4 in phase 3 with the nearest primary completion, of 14 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Dec 2026 est.zamtocabtagene autoleucel · Miltenyi Biomedicine GmbH · Phase 2 named, not the main aimstudied with Cyclophosphamidestudied with fludarabinestudied with bendamustineNCT04792489 DALY II USA/ MB-CART2019.1 for DLBCL — primary endpoint: Objective Response Rate · 315 enrolled
  • 15 Feb 2027 est.acalabrutinib · AstraZeneca · Phase 3 main aimadded to Rituximabadded to bendamustineNCT02972840 A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL — primary endpoint: Progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2 · 635 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Lymphoma, Mantle-Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 44 open · Alkylating agents 5 open · Antimetabolites 4 open · Antibody-drug conjugates (ADCs) 4 open · Proteasome inhibitors 1 open

Coming up

71studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 124 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger. 14 (11%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (2%) take healthy volunteers.

Recruiting studies that take each age, of 124
AgeWomenMen
107 (6%)7 (6%)
18118 (95%)118 (95%)
30120 (97%)120 (97%)
40120 (97%)120 (97%)
50120 (97%)120 (97%)
65123 (99%)123 (99%)
75118 (95%)118 (95%)
85100 (81%)100 (81%)

Across all 1,221 studies, recruiting or not: 22% stop at 75 or younger and 10% at 65; 18% take children; 0% are for women only and <1% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lymphoma, Mantle-Cell studies take

Of 183 phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 63 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 161 mo36–82 · 128 studies57 mo31–71 · 55 studies64 mo39–98 · 73 studies
Phase 1/275 mo45–114 · 77 studies—78 mo49–122 · 51 studies
Phase 263 mo38–106 · 183 studies49 mo22–87 · 30 studies64 mo40–108 · 153 studies
Phase 397 mo68–… · 27 studies——
Interventional, no phase47 mo22–144 · 18 studies——
Observational60 mo44–121 · 38 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,221. Browse all 1,221 → or search them.